chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I got Pfizer on my first dose due to lack of supply I'm getting Moderna for second dose; This spontaneous case was reported by a patient and describes the occurrence of INTERCHANGE OF VACCINE PRODUCTS (I got Pfizer on my first dose due to lack of supply I'm getting Moderna for second dose) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced INTERCHANGE OF VACCINE PRODUCTS (I got Pfizer on my first dose due to lack of supply I'm getting Moderna for second dose). At the time of the report, INTERCHANGE OF VACCINE PRODUCTS (I got Pfizer on my first dose due to lack of supply I'm getting Moderna for second dose) had resolved.
The first day I started with a sore throat, and I felt a little achy. I didn't sleep that night because of a massive headache I had. In the middle of night two I took Excedrin. In the last couple of weeks I have had on and off headaches. 11/29/2021 I called my doctor because I was feeling poorly.  I was prescribed amoxicillin and 1 other medication. I wasn't getting any better so I called again. I went to see my doctor on 12/6/2021. They did many test. I was prescribed methylprednisolone and have been on that for about 4 days now. Anytime I do anything I am tired. I feel exhausted, but I'm starting to feel a little bit better.
sudden hearing loss requiring hear aids, ear canal swelling and itching, axillary gland enlargement and pain
Information has been received from a nurse practitioner (N.P.) concerning a 22 year old female with allergy to SEPTRA who on 07-FEB-2011 was vaccinated with the first dose of GARDASIL (lot # 666596/0414Z, exp. 15-OCT-2012). The reporter stated that the patient had a "swollen arm and throbbing arm pain which started approximately 2 weeks after the first dose of GARDASIL was given on 24-FEB-2011". No treatment was given for the adverse event. The reporter also stated that it took 11 days for the patient to recover (07-MAR-2011). It was unknown if the patient sought medical attention. Additional information has been requested.
After receiving the vaccine my arm felt numb and tingly, my fingers also felt a little numb. My heart felt as if it was racing a little fast as well.  Around the third day after the vaccine I had a slight fever and a migraine, that is when I went to seek care about the migraine and was prescribed Tylenol and ibuprofen .  After taking my medicine and resting for a few days since my job gave us a week off for receiving the vaccine they symptoms subsided. A few weeks later, I noticed that I didn't receive my monthly which should have shown up around the last week of each month. So when I went to my doctor for an appointment they gave me a blood test to check and make sure that I was not pregnant and the results came back negative.
PFIZER COVID VACCINE #3 GIVEN 10/19/21, LOT #FE3590; 1/24/22 pt was seen at Medical Center; she had a positive COVID test; 1/26/22 there's record of pt having the COVID infusion without any complications; our records show pt passed away at home on 2/18/22; no other records
Pt began by having numbness in her tongue, then she began to have difficulty swallowing, generalized itching and finally R-leg swelling
My daughter received GARDASIL vaccine from her doctor on 02/23/2009. Since having the injection she has had a severe headache, body aches, upset stomach, dizziness and tingling in her hands and feet.
Staff member started to feel dizzy and lightheaded a few minutes after the injection, with brief episodes of palpitation. Blood pressure taken by physician, measured 180/90. Staff member was given Amlodipine 2.5 mg at 3 pm. Another Amlodipine 2.5 mg given at 4 pm. At 4:30 pm blood pressure was 160/100. Patient symptomatically felt better. At 5:04 pm blood pressure was 150/90. Staff member was observed until 5:15 pm, the discharged home in the care and supervision of her husband. Staff member will follow-up with personal physician.
PATIENT BP DROPPED TO 71/45, PATIENT FELT PALE AND SWEATY.  PATIENT SAT FOR 40 MORE MINUTES AFTER THE ORIGINAL 15 MINUTE WAIT.  AFTER THE WAIT BP INCREASED AND COLOR RETURNED TO FACE.  NO LONGER SWEATING AND HER MOTHER FELT SHE WAS OK TO GO HOME.  THEY REFUSED AN AMBULANCE.  AT 7:30PM BP WAS 97/67 AND PATIENT STATED HERS DOES RUN LOW.  ALSO GAVE ICE PACKS
Patient is a 15 yo M with no significant past medical history who presented with a two week history of worsening ataxia associated with "heaviness" of the head and 15 lb weight loss. Symptoms started on 8/13. Patient received pfizer COVID19 vaccine on 7/26/2021 and 8/16/2021. Initially presented to OSH ED on 8/18 for symptoms where a workup was negative including CBC, CMP, Magnesium, UA, COVID, UDS. CT Head showed no mass effect, hemorrhage or infarction. Was diagnosed with Viral Syndrome and discharged. Two days later (8/20/2021) instability while walking continued as patient could hardly walk. Yesterday evening continued ataxic gait with lightheadedness only on ambulation. No fevers, chills, chest pain, shortness of breath, abdominal pain, nausea, vomiting, vertigo. Of note father states that speech has changed in terms of fluency. Went back to ER on 8/23/2021 where CBC, CMP, ESR, CRP were all negative. Transferred to hospital for further evaluation and workup.   In the hospital he has had unchanged ataxia, workup has been negative thus far. Has normal neurologic exam other than dysmetria on finger-to-nose testing, heel-to shin. Has ataxia falling to left side. Still hospitalized but starting on IVIG empirically.
light headed, dizzy; blood pressure was taken and registered at 235/105; This is a spontaneous report from a contactable consumer (patient). A 65-year-old female patient received 1st dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration in left arm on 03Feb2021 12:00 at single dose for COVID-19 immunisation. The patient's medical history was not reported. Concomitant medication included allopurinol (ALLOPURINOL). No other vaccine in four weeks. The patient previously took morphine and experienced allergies. Immediately upon receiving the vaccine (03Feb2021 12:00), The patient became light headed, dizzy. Her blood pressure was taken and registered at 235/105 (on 03Feb2021), she was taken to the emergency room. She remained there for 2-3 hours then sent home. Events treatment: EKG. The events resulted in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care, hospitalization for 1 day, Life threatening illness (immediate risk of death from the event). The outcome of events was not recovered. The patient was not pregnant. No covid prior vaccination. No covid tested post vaccination.  information on the lot/batch number has been requested.
Sore arm; This case was reported by a consumer via call center representative and described the occurrence of pain in arm in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 8th March 2022, the patient received the 1st dose of Shingrix. On 8th March 2022, less than a day after receiving Shingrix, the patient experienced pain in arm. On an unknown date, the outcome of the pain in arm was recovered/resolved.   It was unknown if the reporter considered the pain in arm to be related to Shingrix.  Additional details reported were as follows: This case was reported by the patient for herself. The age at vaccination was not reported. After receiving Shingrix, the patient had a sore arm that lasted for 20 minutes. The patient enquired that for patients 50 years or older, was there a time that was preferred in the 2 to 6 month time-frame to get second dose of Shingrix.  The patient did not wish to provide any further details. The consent to follow-up was not given.
Severe allergic reaction; headache; tired within 5 minuets; about 30 minuets in it turned to nausea; then throat started to feel tight; wheezing in lungs; Lips tingling; Face tingling; Eyes went itchy; This is a spontaneous report from a contactable consumer.  A 28-years-old female patient received bnt162b2 (BNT162B2), dose 1 via an unspecified route of administration, administered in Arm Left on 20Aug2021 15:30 (Batch/Lot number was not reported) (at the age of 28-years-old female ) as single dose for covid-19 immunisation  .  Medical history included covid-19 from an unknown date and obesity. The patient was not pregnant. Concomitant medications included buspirone 40mgs taken for an unspecified indication; escitalopram 25mgs taken for an unspecified indication; hydroxyzine 10 taken for an unspecified indication.  The patient had known allergies to  allergies to Lamictal, abilify and strattera.  On 20Aug2021 at 15:45 the patient had severe allergic reaction. Headache and tired within 5 minuets then about 30 minuets in it turned to nausea then throat started to feel tight with wheezing in lungs, lips and face went tingling and eyes went itchy. The events resulted in Emergency room/department or urgent care. The patient was treated with Iv benadryl, stairoid, histamine uptake, ep shot. Since the vaccination, the patient has not been tested for COVID-19. The outcome of the events was recovering.  The lot number for the vaccine, bnt162b2 was not provided and will be requested during follow up.
Pt standing in post observation awaiting allotted time in  post vaccination.  Pt complaining to family members that the "room is spinning ".  1709 RN called and assessed alert man complaining of headache, denies breathing difficulty, lightheadedness, and nausea. EMTS called and arrived at 1710 Pt seated and BP 142/84 HR60 O2sat 97RA.  Pt given H20 and resting in chair and monitored my EMTs.  Pts symptom of dizziness is resolved and discharged at 1720.
Initial report received on from an investigator participating in the trial under the reference number H-406-004 and 06 December 2011. A male subject (date of birth not reported) with no relevant medical history had received ACAM2000 (lot number not reported) on 14 November 2011. Seven days post inoculation/vaccination on 21 November 2011, the subject experienced severe right lower quadrant abdominal pain without a fever. The subject was taken to the hospital and admitted on 21 November 2011. The next day on 22 November 2011, the subject had surgery. The surgeon reported the subject's appendix was gangrenous but not ruptured. The subject was placed on the following post-op medications: oral trimethoprim and SEPTRA DS 800/160 milligrams (mg) twice a day (BID) for 5 days, oral FLAGYL 500 mg three times a day for 5 days, acetaminophen and PERCOCET 5/325 mg as needed (max 1-2 x 6 hours per day), and ibuprofen 600 mg as needed (up to 3 times per day). The subject had an uncomplicated recovery and was discharged from the hospital on 24 November 2011. The subject had returned to duty. The outcome was reported as recovered on 24 November 2011. Note: Information was collected from the physician since the subject was not present for his V2 follow-up. The investigator indicated that a causal relationship to the vaccine was considered remote. Documents held by sender: None.
Child received vaccine at 0930 and had no reaction at that time.  Three hours later a fever was reported of 101.5 F and was proceeded by 3 bouts of NBNB emesis.  Child became less responsive and was not showing a vigorous cry.  Child was treated at ER and released after diagnosis of probably adverse reaction to vaccines.
Within 2 days of receiving the rotavirus vaccine, the color of patient's stool began to change, from brown to reddish brown to frank red blood. We had already seen a gastroenterologist due to what they thought had been a dairy allergy a month or so prior to this, so we went back to their office. I explained my fear of intussusception, to which the Nurse Practitioner told me that patient was too young. However, that's a false statement because intussusception is actually listed as a serious problem following the rotavirus vaccine right on the CDC website, and the first dose of the vaccine is recommended at 2 months old. Moving forward, I asked that their office order an abdominal ultrasound. The soonest I could get patient in for the US at Medical Center was the following week. In the meantime, I asked Dr. to order an US as well and called Medical Center to see if they could get us in any sooner. They were able to get us in 2 days sooner, so we went there. The results ruled out intussusception, however, were still mostly inconclusive. At this point, the blood was so bad, the next day, August 18th, 2016, Dr. referred us to the Emergency room. So now, my 2 month old baby, who has already been through open heart surgery, has to go through a multitude of testing, including IV sticks, IV fluids, stool tests, urine tests, and blood draws... all negative besides a  low hemoglobin, due to the bleeding, but not low enough to transfuse as well as a slightly decreased kidney function. The Medical Center emergency room did not complete an ultrasound, so we brought him back for his originally scheduled appointment, which showed an essentially negative ultrasound. Finally, after several weeks to months, the frank blood stopped, but to this day, almost 1 year later, patient's stool still shows microscopic blood when tested with an occult stool card.
I received dose 1 on 1/4/21 with relatively few side effects (no side effects I was not expecting). After receiving dose 2 on 2/1/21, I experienced more severe systemic side effects (fatigue, chills, muscle aches, headache) that started the next day on 2/2/21.  On 2/3/21, I noticed I had some discomfort while sitting down. By 2/4/21, I had noticed vaginal ulcerations that had formed on the vulva. I immediately made an appt to be seen by my Obgyn the next day on 2/5/21. I shared the following information with my obgyn during the appt: this was the first time I had ever noticed this, I have rheumatoid arthritis and am currently on Rituxan (rituximab) and get every 6 months, and I have been in a monogamous relationship for 2+ years. My Obgyn and I suspected that this was herpes and possibly had been dormant for many years.   However, herpes tests came back negative. I was then referred to an Obgyn who specializes in ID, and she was able to tell me by looking at the lesions that this was not an STI. She highly suspects the vulvar ulcerations are autoimmune in nature, and she mentioned that it was a Lipschutz ulcer.   While the trigger is not clear at this time, I am thinking there is a possibility that the second COVID vaccine dose could be what triggered the formation of these ulcers.
Initial needle puncture made in error with syringe with no contents - air, gas, liquid or otherwise.  Syringe plunger was depressed without any movement of plunger.   Administration error noted by Vaccinator post attempted vaccination and subsequently reported issue to Lead.  All supplies and doses were reconciled, patient mother notified and verbal consent obtained to vaccinator to proceed with vaccination of the patient.  Full dose of vaccine was provided and verified - given without further incident.
Swelling from injection site to mid forearm. Area reddened and warm to touch. Patient noticed area being painful. Deltoid 11" at below elbow 11" in diameter. Seen by doctor; antibiotic and samples of Clarinex given.
arm was red; arm tenderness; This spontaneous case was reported by a patient and describes the occurrence of PAIN IN EXTREMITY (arm tenderness) and INJECTION SITE ERYTHEMA (arm was red) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 08-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Jan-2021, the patient experienced PAIN IN EXTREMITY (arm tenderness). On 20-Jan-2021, the patient experienced INJECTION SITE ERYTHEMA (arm was red). On 10-Jan-2021, PAIN IN EXTREMITY (arm tenderness) had resolved. At the time of the report, INJECTION SITE ERYTHEMA (arm was red) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.   No treatment information was provided.
DAY 1 - SORENESS - 10-29-07 DAY 2 - SORE & SWOLLEN DAY 3 - TINGLING & NUMB & PAIN TO NECK DAY 4 - DISCOLORATION, RED BLOTCHES TO ARM, HA DAY 5 - CIRC. PROBLEMS TO ARM WENT TO ER. HAD MRI  DONE. - IS DOING BETTER 11/6/07
Information has been received from a female consumer, reporting on herself, who on 20-MAY-2011 was vaccinated with a dose of ZOSTAVAX (Merck) (lot #, dose and route not reported). Consumer reported that, on an unknown date, she developed a rash at the injection site. It was unknown if patient sought medical attention. At the time of the report, the patient's outcome was not recovered. Additional information is not expected.
pt had redness, warmth & swelling @ site of inj of vax;(but problem occurred 1k p/vax;encouraged heating pad & to see PMD if not better;(redness & induration about 4in-x 2in;
Swelling in right side of neck lymph node; Tenderness in neck lymph node; This spontaneous case was reported by a consumer and describes the occurrence of LYMPHADENOPATHY (Swelling in right side of neck lymph node) and LYMPH NODE PAIN (Tenderness in neck lymph node) in a 46-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 002A21A and 037K20A) for COVID-19 vaccination.     No Medical History information was reported.   On 15-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 24-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 25-Feb-2021, the patient experienced LYMPHADENOPATHY (Swelling in right side of neck lymph node) and LYMPH NODE PAIN (Tenderness in neck lymph node). At the time of the report, LYMPHADENOPATHY (Swelling in right side of neck lymph node) and LYMPH NODE PAIN (Tenderness in neck lymph node) outcome was unknown.            Concomitant medication list was not provided. Treatment information was not provided. Action taken with mRNA-1273 in response to the event was not applicable.
One week after vaccine administration, patient developed an itchy rash in the night. The rash continued to worsen and expand in diameter. The area was red, hot, and sore.  Patient was told to contact her primary care physician, take diphenhydramine and apply a topical hydrocortisone to help reduce redness and itching while waiting for doctors directions.
Pfizer BioNTech COVID-19 Vaccine EUA: COVID-19 case resulting in Hospitalization / Death. Patient received Pfizer Vaccines on 1/13/2021 and 2/2/2021. Presented to ED on 8/6/2021 with complaints of acute worsening of weakness of bilateral extremities s/p fall. Of note patient reports he has had a cough since the last week of July. In the emergency room vital signs was slightly elevated blood pressure and temperature up to 101.1° F, saturating well on room air. EKG reviewed with slightly worsened ST depressions in inferior lateral leads with a known right bundle branch block. Patient underwent an EGD on 8/7 which revealed erosive gastritis. Patient oxygen requirement increased on 8/12/2021. Dexamethasone started on 8/12/2021. LLL early consolidation seen on CXR on 8/12/2021 that was not present on admission. Remdesivir started on 8/13/2021. On 8/21/2021 patient's family requested to transition to comfort care. Patient expired on 8/21/21.
Information has been received from a Registered Nurse concerning a female who was vaccinated with pneumococcal 23 v polysaccharide vaccine. Concomitant therapy included influenza virus vaccine (unspecified). Subsequently, the patient experienced an elevated response and flu-like symptoms. Subsequently, the patient recovered from her experiences. Additional information has been requested.
Wheal - 2 - 2 1/2" diameter. Inflamed - hot to touch. Left arm pain.
Area of induration, 1cm X 1cm, erythema, developed 48 hours post vax.
10/11/21 - #3 COVID vaccine on 10/9. started experiencing chest pain and body aches.  Chest pain is  gradually subsiding. Denies SOB or other cardiac symptoms
severe injection site soreness (left arm) about 12-16 hours post moderna covid vaccine dose 1.  Severe tension headaches daily on days 2-5 post vaccine that could not be linked to other causes
Patient began screaming unconsolably and it lasted all night, then off and on for the next few days. It was a high pitched cry/scream. He started banging his head on his crib and that continued periodically for months. He also had loose stools starting that night which continued forever 2 years.
No adverse event; 0.25ml dose administered instead of 0.5mL; This spontaneous case was reported by a nurse and describes the occurrence of ACCIDENTAL UNDERDOSE (0.25ml dose administered instead of 0.5mL) and NO ADVERSE EVENT (No adverse event) in a 76-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 030G22B) for COVID-19 prophylaxis.     No Medical History information was reported.    On 18-Oct-2022, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) .25 milliliter. On 18-Oct-2022, the patient experienced ACCIDENTAL UNDERDOSE (0.25ml dose administered instead of 0.5mL). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, ACCIDENTAL UNDERDOSE (0.25ml dose administered instead of 0.5mL) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for ACCIDENTAL UNDERDOSE (0.25ml dose administered instead of 0.5mL).    No concomitant products reported.  It was reported that it had been brought to attention that the patient had been given 0.25mL of Moderna Bivalent booster vaccine. Asked for advise if the 0.25mL dose was enough coverage for the patient. Questioned if the patient need to receive another 0.25mL dose.  This case was for one of the patient among the 14 patients who received 0.25mL of Moderna Bivalent booster vaccine.   No treatment products reported.
Pt recvd 3 doses of Engerix-B 8NOV90; 11DEC90 & 28MAY91; 29JUN91 tested for Anti-HBS & found to be non-reactive; 10JUL91 recvd 4th dose; 21AUG91 tested for anti-HBS & found to be reactive @ a subtherapeutic level; pt not considered immune;